Naimish Patel - Oct 16, 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Oct 16, 2024
Transactions value $
$0
Form type
4
Date filed
10/18/2024, 05:35 PM
Previous filing
May 28, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +18.3K $0.00 18.3K Oct 16, 2024 Common Shares 18.3K $49.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024.